Search Constraints
« Previous |
1 - 20 of 85
|
Next »
Search Results
Select an image to start the slideshow
New chemical approaches for the development of targeted protein degradation
1 of 20
Development of lysine-targeted irreversible inhibitors of PI3Kδ
2 of 20
Pharmacological characterisation of small molecule RGD-mimetics targeting αvβ6-mediated activation of TGFβ in idiopathic pulmonary fibrosis
3 of 20
The interplay of multiple ADME mechanisms : prediction of hepatic drug-drug interactions from in vitro
4 of 20
New treatments for inflammatory diseases : optimisation and understanding of key processes
5 of 20
Novel heterocyclic ligands for the lipid kinase PI4KIIIβ : a chemical biology approach
6 of 20
Electrochemically enabled synthesis of substituted isoxazolines
7 of 20
The design, synthesis and optimisation of CCR4 antagonists for the treatment of asthma
8 of 20
Utilisation of rearrangement chemistry in the synthesis of novel fluorinated ring systems : a computational and experimental study
9 of 20
The design and synthesis of αvβ6 antagonists and PI3K inhibitors as small molecule therapies for respiratory diseases
10 of 20
Novel PI3Kδ inhibitors for the treatment of inflammatory diseases
11 of 20
Chemoselective C-H functionalisation of aliphatic azacycles : utilisation of electrophilic iodine as a mild oxidant
12 of 20
αV integrin antagonists for the treatment of idiopathic pulmonary fibrosis
13 of 20
The design, synthesis and optimisation of αvβ6 antagonists as potential idiopathic pulmonary fibrosis agents
14 of 20
The use of structure-based drug design to optimise protein-ligand interactions
15 of 20
Early application of mechanistic PKPD modelling to guide the preclinical development of a therapeutic mAb targeting complement receptor 2 (CR2/CD21) as a novel target for the treatment of autoimmune disease
16 of 20
Development and understanding of rhodium-catalysed conjugate arylation for process chemistry applications
17 of 20
Expanding the scope of asymmetric redox-relay oxidative Heck transformations
18 of 20
Preclinical development of a treatment for systemic lupus erythematosus
19 of 20
Iron-catalysed cross-couplings of secondary alkyl Grignard reagents
20 of 20